ScoreHaematology
NCCN-IPI in diffuse large B-cell lymphoma
Enhanced DLBCL prognostic index that grades age and LDH and counts extranodal involvement of key organs.
Updated 31 October 2026
When to use it
Patients with DLBCL at diagnosis treated with rituximab-based immunochemotherapy, to estimate overall survival.
What it needs
- Age
- LDH (ratio to upper limit of normal)
- Ann Arbor stage III–IV
- Bone marrow, CNS, liver/GI tract or lung involvement
- ECOG ≥ 2
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 1 | Low risk (0–1) |
| 2–3 | Low-intermediate risk (2–3) |
| 4–5 | High-intermediate risk (4–5) |
| ≥ 6 | High risk (6–8) |
Practical tip
It separates the extremes better than the IPI: 5-year OS ≈ 96% in low risk versus ≈ 33% in high risk.
2 more practical tips in the app.
Reference
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
